We use cookies to enhance your browsing experience, analyze website traffic, and maintain essential site functionality. By clicking "Accept All", you consent to our use of cookies. For more details, please review our Privacy Policy.

Jazz Pharmaceuticals Stock (NASDAQ:JAZZ)



Previous Close

$109.44

52W Range

$95.49 - $148.06

50D Avg

$108.80

200D Avg

$118.22

Market Cap

$6.65B

Avg Vol (3M)

$1.10M

Beta

0.33

Div Yield

-

JAZZ Company Profile


Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in narcolepsy patients seven years of age and older; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia; and Zepzelca for the treatment of adult patients with metastatic small cell lung cancer. The company also offers Xywav, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for narcolepsy patients; JZP385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and JZP150 for treatment of post-traumatic stress disorder. The company has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc. Jazz Pharmaceuticals plc was incorporated in 2003 and is headquartered in Dublin, Ireland.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IE

Employees

2,800

IPO Date

Jun 01, 2007

Website

JAZZ Performance


Total Return %
1D
5D
1M
3M
6M
YTD
1Y
3Y
5Y
10Y
JAZZ
S&P 500
0.44%
1.49%
-0.36%
-9.02%
-8.83%
-11.18%
6.17%
-31.32%
-1.15%
-38.25%
0.45%
1.24%
4.09%
15.60%
4.81%
6.13%
12.51%
62.44%
95.69%
200.14%

Latest Earnings Call Transcripts


Q2 22Aug 03, 22 | 6:53 PM
Q1 22May 05, 22 | 12:50 AM
Q4 21Mar 01, 22 | 9:52 PM

Peer Comparison


TickerCompany
ALNYAlnylam Pharmaceuticals, Inc.
BMRNBioMarin Pharmaceutical Inc.
INCYIncyte Corporation
UTHRUnited Therapeutics Corporation
GMABGenmab A/S

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools